This article is more than 5 years old. Information may no longer be current.

Proton therapy planning device for ocular cancer given 501(k) clearance

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PALO ALTO, Calif. — A calculation module for planning radiation treatments for eye cancers has been granted Food and Drug Administration 510(k) clearance, according to the device’s maker. The new proton therapy eye dose calculation module will be part of the Varian Eclipse treatment planning system, Varian said in a press release.

Varian Medical System’s proton eye dose calculation module is designed to let doctors “precisely deliver proton radiation beams for treatment of ocular cancers while maximizing protection” for the structures in and around the eye, the press release said.

Proton radiotherapy is currently available in only a few treatment centers worldwide, the Varian release said. With the addition of this module, these centers will be able to treat cancers of the eye using this form of radiation therapy, Varian said.